Masimo wins two awards as Danaher takes Masimo Corporation stock private

Masimo won two OCTANE High Tech Awards on September 30, 2026, while Danaher completed its acquisition of Masimo on June 10, 2026. PR Newswire said the awards recognized the USD 9.9 billion transaction and the leadership team guiding Masimo inside Danaher's Diagnostics platform.

Danaher closes the transaction

Danaher announced on June 10, 2026, that it had completed the acquisition of Masimo Corporation. The deal converted each Masimo share into USD 180.00 in cash and ended Masimo's separate Nasdaq listing.

The transaction changes the investment case from a public-company stock story to an operating-business story inside Danaher's Diagnostics segment. For investors tracking the former MASI listing, the key reference is the fixed cash consideration rather than a continuing standalone earnings multiple.

Healthcare results before the deal

Masimo's latest reported quarter before the transaction ended April 4, 2026. According to StockTitan, revenue from continuing operations reached USD 403.6 million in the first quarter of 2026, compared with USD 372.0 million a year earlier, a 8.49 percent increase.

The same filing summary reported USD 57.1 million in net income for the first quarter of 2026, versus a USD 170.7 million loss in the prior-year period. Continuing operations produced diluted earnings per share of USD 1.09, while merger-related costs reached USD 17.9 million.

Former MASI market reference

Masimo's last structured Nasdaq quote stood at USD 179.95 on June 12, 2026, matching the prior close. That historical level sat close to the USD 180.00 cash consideration and illustrates how the market price converged with the announced transaction value before the delisting.

More news and analyses on Masimo Corporation stock